Rejoyn™: Transforming Depression Treatment Through Prescription Digital Therapeutics

Mental health care is evolving with the introduction of prescription digital therapeutics (PDTs), bridging gaps in accessibility, affordability, and stigma in traditional treatments. Leading this transformation is Rejoyn™, the first FDA-authorized prescription app for managing Major Depressive Disorder (MDD) symptoms. Designed as a supplement to antidepressant medication, Rejoyn delivers evidence-based tools directly to patients, fostering active participation in their mental health journey.

Why Digital Therapeutics?

Challenges such as provider shortages, high costs, and lingering stigma hinder mental health care. PDTs like Rejoyn offer a novel solution—accessible, nonpharmacological treatments that integrate seamlessly into patients' lives.

Rejoyn targets depression symptoms using a combination of cognitive-emotional training (CET) exercises and cognitive behavioral therapy (CBT)-based lessons, harnessing neuroplasticity to address communication gaps in the brain. By strengthening connections between the amygdala and prefrontal cortex, the app helps patients better process emotions.

A Structured Approach

Rejoyn’s 6-week program includes:

• Brain-training exercises: 20-30 minutes, three times per week, tailored to patient progress.
• CBT-based video lessons: Five-minute sessions teaching practical skills, such as reframing negative thoughts and managing strong emotions.

After completing the initial program, patients can access therapy lessons for an additional four weeks.

“Rejoyn isn’t a replacement for medications or therapy,” says Daniel Carpenter, Senior Director of Global Digital Therapeutics Product Development at Otsuka Precision Health, Inc. (OPH). “It’s an adjunctive treatment for those needing extra support.”

Proven Effectiveness

A 13-week remote trial confirmed Rejoyn’s effectiveness, showing reduced depressive symptoms without side effects. This makes it an ideal option for patients partially responsive to antidepressants, offering a complementary, nonpharmacological pathway to relief.

Accessibility and Affordability

Patients can access Rejoyn by consulting their healthcare provider or initiating a virtual consultation via rejoyn.com. Prescriptions are fulfilled by BlinkRx, with the program currently available at an introductory price of $50 (full price: $200).

A Brighter Future for Mental Health Care

Rejoyn exemplifies how PDTs can revolutionize treatment, empowering patients while advancing understanding of brain health. “The more we understand the brain, the better we can treat conditions like depression,” Carpenter emphasizes.

With innovative tools like Rejoyn, mental health care is becoming more accessible, personalized, and effective. Talk to your provider or visit rejoyn.com to explore this groundbreaking treatment option.

(Rejoyn is not a standalone treatment and must be used alongside prescribed medications. For safety information, visit rejoyn.com/IFU.)